Hints and tips:
Related Special Reports
...It has also worked on drug development for US pharma company Johnson & Johnson, Danish biotech group Genmab and British biotech Iksuda therapeutics....
...Japan’s sovereign development bank is investing in UK life sciences for the first time with funding for 4Bio Capital, a UK venture fund that backs advanced treatments such as cell and gene therapies....
...[Enlarge] Further reading:— Alert: Alphaville LLC issues new research report on Duchy of Cornwall (FTAV)— Greenland: Alphaville put on its sellside hat for the deal of the century (FTAV)— Alphaville LLC...
...Lab monkey prices in China have plummeted as a post-pandemic slowdown in drug development ripples through the pharmaceutical sector in the world’s second-largest economy....
...It has pledged to double funding for dementia research to £160mn a year by 2025....
...Developing new antibiotics is often unattractive for pharmaceutical companies, as research and development costs are high but their use is designed to be limited to reduce the risk of the product driving...
...Citadel, which manages roughly $61bn, made a record $16bn in profit for investors in 2022, according to research from LCH Investments....
...Jodie Keane Senior Research Fellow ODI (Formerly Overseas Development Institute), London SE1, UK...
...In March Johnson’s team said of his visit to Venezuela that he was acting as a diplomatic back channel for the UK with the “active support” of the Foreign, Commonwealth and Development Office....
...It has 178 prospects at various stages of development; it has been striking a series of deals, including last month’s $2.4bn agreement to buy Canadian biotech Fusion Pharmaceuticals aimed at bolstering its...
...Susan Galbraith, executive vice-president of oncology research and development at AstraZeneca, said there was an “opportunity to improve” on existing drugs in the area and that the Fusion acquisition would...
...One of his most well-known contributions to research is the ‘Sally-Anne task’....
...Many biotechs hoping to enter the market will aim for partnerships with larger groups, a well-trodden path in the pharmaceutical industry....
...Spravato, a nasal spray based on a molecule from the psychedelic drug ketamine used to treat depression, already ranks as Johnson & Johnson’s fastest-growing product....
...Johnson’s team have said he had acted as a “diplomatic back channel for the UK”, but the Foreign, Commonwealth and Development Office said he was “not acting on behalf of the UK government”....
...Pointing to the risks of unnecessary treatment, Cancer Research UK said over-diagnosis could have “a negative psychological impact”, and treatment of prostate cancer could also cause physical side effects...
...This meant a significant proportion of cancer research was only possible because of public donations, she added....
...High demand for weight-loss drugs has helped Novo Nordisk become Europe’s largest company by market capitalisation, while Eli Lilly overtook Johnson & Johnson as the world’s largest pharmaceutical company...
...“They end up being clustered around genes that are altered in cancer in a variety of different ways, providing the first glimpse that these sequences may be key to tumour development,” he said....
...Wegovy, alongside Eli Lilly’s tirzepatide-based drugs, which are both administered via weekly injections, are expected to generate $18.2bn in global sales this year, according to projections by research...
...The results from the research, which involved 156 people, were a “major breakthrough”, said Olivier Rascol, a Toulouse University Hospital professor and a co-author of the research with Prof Wassilios Meissner...
...David Moore, vice-president for corporate development, added that the company would focus on acquisitions in diabetes and obesity, ideally in the early stage of development....
...Novo Nordisk purchased Dicerna Pharmaceuticals, a company focused in RNA-based therapeutics, for $3.3bn in 2021....
...In contrast, pharmaceutical companies raised just $160mn for antibiotic research, a decline over the decade. Commercial activity and research in antibiotics have been in decline since the 1980s....
...In October, pharmaceuticals companies Eisai and Eli Lilly unveiled research showing the benefits of using new Alzheimer’s drugs very early in the development of the disease....
International Edition